mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland.

Hilty, Matthias Peter; Keiser, Stefanie; Wendel Garcia, Pedro D; Moser, André; Schuepbach, Reto A

Hilty, Matthias Peter; Keiser, Stefanie; Wendel Garcia, Pedro D; Moser, André; Schuepbach, Reto A.

Hilty MP; Institute of Intensive Care Medicine, University Hospital of Zurich, Zurich, Switzerland. matthias.hilty@usz.ch.
Keiser S; Institute of Intensive Care Medicine, University Hospital of Zurich, Zurich, Switzerland.
Wendel Garcia PD; Institute of Intensive Care Medicine, University Hospital of Zurich, Zurich, Switzerland.
Moser A; CTU Bern, University of Bern, Bern, Switzerland.
Schuepbach RA; Institute of Intensive Care Medicine, University Hospital of Zurich, Zurich, Switzerland.

Intensive Care Med ; 48(3): 362-365, 2022 03.

Article in English | MEDLINE | ID: covidwho-1633252

Subject(s)

COVID-19; SARS-CoV-2; COVID-19 Vaccines; Critical Illness; Humans; Intensive Care Units; RNA, Messenger; Severity of Illness Index; Switzerland; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Intensive Care Med Year: 2022 Document Type: Article Affiliation country: S00134-021-06610-Z

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google